DGAP-News: Biotest AG
/ Key word(s): Statement
Dreieich, 4 October 2020. Bloomberg reported on 2 October 2020 that, according to informed circles, a private equity firm had approached the Chinese Creat Group Corp. to acquire a stake in Biotest AG. The consultations are at an early stage and there is no certainty that they will lead to a transaction.
The company believes that this is pure market speculation.
Such rumours and speculations are not new and are known to Biotest. The Management Board has therefore recently asked for a statement from the major shareholder on the plans with regard to the stake in the company. In a written communication to the Company, Creat Group Corp. has stated that no sale process has been initiated to date, nor has any decision been made regarding a future sale. The decision process regarding the future of the majority stake in Biotest AG is completely open, so that rumours of a sale are pure speculation.
Biotest AG will continue to inform the capital market and the public in accordance with the legal requirements.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
04.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1138735|
|End of News||DGAP News Service|